

In the claims:

Please amend claims 3, 4, 5, and 8 and add claims 9-15.

1. (Original) An examination method to predict prognostic effects in immunotherapy for pancreas cancer, comprising determination of intrinsic IL-12-producing ability.

2. (Original) The examination method according to claim 1, wherein the prognostic effects are predicted by dividing the IL-12-producing ability into a plurality of, i.e. at least three groups of 50 pg/ml or more, from 7.8 to less than 50 pg/ml, and less than 7.8 pg/ml.

3. (Currently Amended) The examination method according to ~~claim 1 or 2~~ claim 1, wherein the immunotherapy is an IL-12 production-inducing agent.

4. (Currently Amended) The examination method according to ~~any one of claims 1 to 3~~ claim 1, wherein the IL-12 production-inducing agent is a substance having a β -1,3/1,6 glucan structure.

5. (Currently Amended) An IL-12 production-inducing agent, wherein the IL-12 production-inducing agent is administered to a pancreatic cancer patient having IL-12-producing ability of less than 7.8 pg/ml in the examination according to ~~any one of claims 1 to 4~~ claim 1.

6. (Original) A cancer therapeutic agent comprising Gemcitabine Hydrochloride as principal component, wherein the agent is used at least in combination with an IL-12 production-inducing agent.

7. (Original) The cancer therapeutic agent according to claim 6, wherein the cancer is pancreas cancer.

8. (Currently Amended) The cancer therapeutic agent according to ~~claim 6 or 7~~ claim 6, wherein the IL-12 production-inducing agent is administered to a pancreatic cancer patient having IL-12-producing ability of less than 7.8 pg/ml.

9. (New) The examination method according to claim 2, wherein the immunotherapy is an IL-12 production-inducing agent.

10. (New) The examination method according to claim 2, wherein the IL-12 production-inducing agent is a substance having a β -1,3/1,6 glucan structure.

11. (New) The examination method according to claim 3, wherein the IL-12 production-inducing agent is a substance having a β -1,3/1,6 glucan structure.

12. (New) An IL-12 production-inducing agent, wherein the IL-12 production-inducing agent is administered to a pancreatic cancer patient having IL-12-producing ability of less than 7.8 pg/ml in the examination according to claim 2.

13. (New) An IL-12 production-inducing agent, wherein the IL-12 production-inducing agent is administered to a pancreatic cancer patient having IL-12-producing ability of less than 7.8 pg/ml in the examination according to claim 3.

14. (New) An IL-12 production-inducing agent, wherein the IL-12 production-inducing agent is administered to a pancreatic cancer patient having IL-12-producing ability of less than 7.8 pg/ml in the examination according to claim 4.

15. (New) The cancer therapeutic agent according to claim 7, wherein the IL-12 production-inducing agent is administered to a pancreatic cancer patient having IL-12-producing ability of less than 7.8 pg/ml.